期刊文献+

Detection of circulating tumour cells in colorectal cancer:Emerging techniques and clinical implications

下载PDF
导出
摘要 Despite several advances in oncological management of colorectal cancer,morbidity and mortality are still high and devastating.The diagnostic evaluation by endoscopy is cumbersome,which is uncomfortable to many.Because of the intra-and inter-tumour heterogeneity and changing tumour dynamics,which is continuous in nature,the diagnostic biopsy and assessment of the pathological sample are difficult and also not adequate.Late manifestation of the disease and delayed diagnosis may lead to relapse or metastases.One of the keys to improving the outcome is early detection of cancer,ease of technology to detect with uniformity,and its therapeutic implications,which are yet to come."Liquid biopsy"is currently the most recent area of interest in oncology,which may provide important tools regarding the characterization of the primary tumour and its metastasis as cancer cells shed into the bloodstream even at the early stages of the disease.By using this approach,clinicians may be able to find out information about the tumour at a given time.Any of the following three types of sampling of biological material can be used in the"liquid biopsy".These are circulating tumour cells(CTCs),circulating tumour DNA,and exosomes.The most commonly studied amongst the three is CTCs.CTCs with their different applications and prognostic value has been found useful in colorectal cancer detection and therapeutics.In this review,we will discuss various markers for CTCs,the core tools/techniques for detection,and also important findings of clinical studies in colorectal cancer and its clinical implications.
出处 《World Journal of Clinical Oncology》 CAS 2021年第12期1169-1181,共13页 世界临床肿瘤学杂志(英文版)
  • 相关文献

参考文献2

二级参考文献29

  • 1Veronesi U, Boyle P, Goldhirsch A, et al. Breast cancer [J]. Lancet, 2005,365(9472): 1727-1741.
  • 2Peto R, Boreham J, Clarke M, et al. UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years [J]. Lancet, 2000,355(9217): 1822,.
  • 3Eccles SA, Welch DR. Metastasis: recent discoveries and novel treatment strategies [J]. Lancet, 2007,369(9574):1742-1757.
  • 4Nakamura S, Yagata H, Ohno S, et al. Multi-center study evaluating circulating tumor cells as a surrogate for response to treatment and overall survival in metastatic breast cancer [J]. Breast Cancer, 2010,17(3): 199-204.
  • 5Cristofanilli M, Budd GT, Ellis M J, et al. Circulating tumor cells,disease progression, and survival in metastatic breast cancer [J]. N Engl J Med, 2004,351(8):781-791.
  • 6Ring AE, Zabaglo L, Ormerod MG, et al. Detection of circulating epithelial cells in the blood of patients with breast cancer: comparison of three techniques [J]. Br J Cancer, 2005,92(5):906-912.
  • 7Felten T, Harris GC, Pinder SE, et al. Identification of carcinoma cells in peripheral blood samples of patients with advanced breast carcinoma using RT-PCR amplification of CK7 and MUC1 [J]. Breast, 2004,13(1):35-41.
  • 8de Cremoux P, Extra JM, Denis MG, et al. Detection of MUC1-expressing mammary carcinoma cells in the peripheraJ blood of breast cancer patients by real-time polymerase chain reaction [J]. Clin Cancer Res, 2000,6(8):3117-3122.
  • 9Franceschini G, Terribile D, Magno S, et al. Update in the treatment of locally advanced breast cancer: a multidisciplinary approach [J]. Eur Rev Med Pharmacol Sci, 2007,11(5):283-289.
  • 10Andreopoulou E, Cristofanilli M. Circulating tumor cells as prognostic marker in metastatic breast cancer [J]. Expert Rev Anticancer Ther, 2010,10(2): 171-177.

共引文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部